97 studies found for:    pertuzumab
Show Display Options
Rank Status Study
1 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
2 Terminated
Has Results
A Study of Pertuzumab in Participants With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Pertuzumab
3 Recruiting Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Condition: Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab;   Drug: Pertuzumab
4 Completed
Has Results
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Pertuzumab
5 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
6 Active, not recruiting
Has Results
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Conditions: Neuroendocrine Carcinoma;   Neuroendocrine
Interventions: Drug: Bevacizumab;   Drug: Pertuzumab;   Drug: Sandostatin LAR® Depot
7 Completed A Study of Pertuzumab in Combination With Erlotinib (Tarceva) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Pertuzumab
8 Recruiting Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Malignant Tumor of the Breast
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
9 Completed
Has Results
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Placebo;   Drug: Gemcitabine;   Drug: Pertuzumab
10 Completed
Has Results
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: pertuzumab;   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Other: immunohistochemistry staining method;   Other: fluorescence in situ hybridization;   Other: gene expression analysis;   Other: mutation analysis;   Other: polymerase chain reaction;   Other: laboratory biomarker analysis
11 Completed
Has Results
A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Capecitabine;   Drug: RhuMab 2C4
12 Active, not recruiting
Has Results
A Study of Perjeta (Pertuzumab) in Combination With Herceptin in Patients With Metastatic Breast Cancer.
Condition: Breast Cancer
Intervention: Drug: pertuzumab [Perjeta]
13 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
14 Recruiting Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: ganetespib;   Drug: paclitaxel;   Biological: trastuzumab;   Biological: pertuzumab
15 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Breast Adenocarcinoma;   Inflammatory Breast Carcinoma
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
16 Active, not recruiting Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
17 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
18 Recruiting Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Condition: Metastatic Breast Cancer
Interventions: Drug: Pertuzumab;   Drug: Trastuzumab
19 Recruiting Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Condition: Her2-Positive Breast Cancer
Interventions: Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: 5-fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
20 Completed A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Docetaxel;   Drug: RhuMab 2C4

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years